Statement: dust is a fine powdery material such as dry earth or pollen that can be blown about in the air. the results of the secondary trial and the primary trial report the same outcome measures.
Primary_evidence: Outcome Measurement:    Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks   The safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks. The study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI.   Grade 3 or 4 skin/subcutaneous or pulmonary toxicity.   The development of clinical fat necrosis.   The development of rib fracture on the ipsilateral treated side, detected either clinically and/or radiographically.   The data is shown as the number of participants that experienced each of the specific toxicities.   Time frame: 2 years Results 1:    Arm/Group Title: Partial Breast Irradiation   Arm/Group Description: Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks   External Beam Partial-Breast Irradiation: 40 Gy in ten daily fractions over two weeks   Overall Number of Participants Analyzed: 53   Measure Type: Count of Participants   Unit of Measure: Participants  Grade 3 or 4 Skin/ Subcutaneous toxicity: 0   0.0%   Grade 3 or 4 Pulmonary Toxicity: 0   0.0%   Fat Necrosis: 0   0.0%   Rib fractures on ipsilateral treated side: 0   0.0%
Secondary_evidence: Outcome Measurement:    Overall Tumor Response   Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.   Time frame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression Results 1:    Arm/Group Title: Pemetrexed   Arm/Group Description: 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: participants  Complete Response: 1   Partial Response: 8   Stable Disease: 14   Progressive Disease: 9   Best Response Not Evaluable: 3